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Abstract
Background: In Brazil, it is estimated that between 2.5 and 4.9% of the general population present
anti-hepatitis C virus (HCV) antibodies, which corresponds to as many as 3.9 to 7.6 million chronic
carriers. Chronic liver disease is associated with HCV infection in 20% to 58% of the Brazilian
patients. The objective of this case-control study was to investigate the risk factors for presence of
anti-HCV antibody in blood donors in southern Brazil.
Methods: One hundred and seventy eight blood donors with two positive ELISA results for anti-
HCV were cases, and 356 controls tested negative. A standardized questionnaire was used to
collect data concerning demographic and socioeconomic aspects, history of previous hepatitis
infection, social and sexual behaviors, and number of donations. Variables were grouped into sets
of hierarchical categories. Cases and controls were compared using logistic regression, odds ratios,
and 95% confidence intervals. The statistical significance of the associations was assessed through
likelihood ratio tests based on a P value < 0.05.
Results: The prevalence of anti-HCV among blood donors was 1.1%. Most of the donors were
white and males. In the multivariate analysis, independent predictors of anti-HCV positivity were:
intravenous drug use, blood transfusion >10 years earlier, having had two to four sexually
transmitted diseases, incarceration, tattooing, sex with a hepatitis B or C virus carrier or with
intravenous drug users.
Conclusion: Intravenous drug use, blood transfusion, and tattooing were the main risk factors for
anti-HCV positivity among blood donors from southern Brazil, but sexual HCV transmission should
also be considered.
Background
The worldwide prevalence of hepatitis C virus infection is
estimated by the World Health Organization (WHO) to
be approximately 3% – corresponding to 170 million in-
fected persons [1,2]. In Brazil, WHO estimates suggest
that between 2.5 and 4.9% of the general population
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present anti-HCV antibodies [3]. This corresponds to as
many as 3.9 to 7.6 million chronic carriers at risk for de-
veloping liver cirrhosis and/or liver cancer. Studies show
that among Brazilian patients with chronic liver disease,
20 to 58% are anti-HCV positive [4], and that in southern
Brazil 27% of the patients with hepatocellular carcinoma
are anti-HCV positive [5].
While the search for an effective therapy [6] and vaccine
[7] continues, prevention and control of HCV infection
should be the goals of public health efforts. Preventive
strategies aim to reduce the exposure to HCV should be
based on blood testing of individuals, screening of blood
and blood products, sterilization of reusable equipment,
destruction of potentially contaminated disposable in-
struments, and promotion of barrier methods of contra-
ception to prevent sexually transmitted diseases [2]. To
increase the efficacy of these interventions, it is important
that the main risk factors for HCV infection in different
populations be known. Therefore, the present case-con-
trol study was designed to evaluate risk factors in a repre-
sentative sample of blood donors in southern Brazil.
Methods
Study population and design
A sample of blood donors was randomly selected from
eight blood centers in Porto Alegre, state of Rio Grande do
Sul, Brazil, out of 11 centers available in the city. Three
centers were not included due to the small number of do-
nors. The number of blood donors sampled was propor-
tional to the number of donors of each center. A standard
predonation interview was conducted at each center to ex-
clude donors potentialy ill or who reported previous hep-
atitis or jaundice, and drug addiction. Cases were donors
with two positive enzyme-linked immunosorbent assay
(EIA) results for anti-HCV carried out using the same
manufacturers' kits. Controls were blood donors who test-
ed negative for anti-HCV. Two frequency-matched con-
trols were selected next to a case in the same center.
Blood tests
All blood samples were screened for anti-HCV, hepatitis B
surface antigen, hepatitis B core antibody, HIV-1, human
T-cell lymphotropic virus types 1 and 2, syphilis (Sexually
Transmitted Disease Research Laboratory), Trypanosoma
cruzi (etiologic agent of Chagas' disease) and alanine ami-
notransferase (ALT), using licensed assays. Serological
testing for HCV was performed according to standard pro-
cedures at the eight blood centers. Initial screening was by
second-generation EIA and, after January 1996, by third-
generation EIA. The type, generation, and manufacturer of
tests varied with blood center.
Data collection
Data were collected between August 1995 and October
1996. We collected information concerning demographic
(gender and age) and socioeconomic (education) aspects,
parenteral exposure to blood or blood products, social
and sexual behavior, occupational exposure, personal his-
tory of jaundice or hepatitis or history of these diseases in
the donor's family, and signs and symptoms of human
immunodeficiency virus infection. All patients agreed to
participate and signed a consent form. Research assistants
interviewed cases and controls on a private room at each
center, using a standardized questionnaire. Because of the
sensitive character of some questions, female or male in-
terviewers were assigned according to the gender of the re-
spondent. The pretested instrument, which was identical
for cases and controls, included questions concerning de-
tailed history of blood exposure on previous transfusion
and occupational hazard (unintentional needle-stick inju-
ries, for instance), intravenous drug use, tattooing, acu-
puncture, surgery, previous hospitalization and parenteral
administration of drugs. Other questions included age at
first intercourse, number of sexual partners (risk category
was determined separately for men and women according
to the median), history of sexually transmitted diseases -
STD- (gonorrhea, syphilis, or an open sore), sex with part-
ners who had been intravenous drug users or who had
had hepatitis.
Sample size calculation and data analysis
The calculated sample size of 411 donors (137 cases and
274 controls) allowed detection of a 2.0 odds ratio (OR),
with an 80% power at a 0.05 significance level (two
tailed), and an exposure prevalence ranging from 15 to
50%. The sample size was increased in approximately
30% to allow assessment of less prevalent types of expo-
sure and adjustment for confounding variables on multi-
variate analyses.
Data entry was checked for consistency and accuracy using
the Epi-Info software, version 6.04, and the analysis was
conducted using the Statistical Package for the Social Sci-
ences, version 8.0.
Cases and controls were compared using logistic regres-
sion analysis through odds ratios (OR) and 95% confi-
dence intervals (95%CI). Variables were grouped into sets
of hierarchical categories that guided the analysis [8]. The
hierarchy assumes that each set of distal variables influ-
ences the level immediately below or the same level; how-
ever, the distal set is not affected by proximal
determinants, since it is likely that the effect of this distal
set will be mediated through the proximal determinants
(Figure 1). According to this conceptual model, the socio-
economic level may determine all variables being studied,
except for gender and age. The variables associated (P ≤BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/18
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0.10) with presence of a positive anti-HCV test in the uni-
variate analyses were selected to be part of the final model.
Independent risk factors were evaluated after adjustment
for confounding variables in the same set or in hierarchi-
cally superior sets. This approach enables quantification
of the contribution of each level of adjustment, under-
standing of the model-building strategy, and interpreta-
tion of independent associations. Crude as well as
adjusted odds ratios were presented according to the hier-
archical framework. The presence of confounding bias
was detected through the change in odds ratio before and
after adjustment for confounding factors. The adjusted
odds ratio did not result from the full model with all var-
iables, but from the equation corresponding to the level in
which each risk factor was first entered. This avoids the
possibility that intermediate variables will remove some
of the explanatory power of more distant determinants.
The statistical significance of the associations was assessed
through likelihood ratio tests based on a P value < 0.05.
Results with a P value > 0.05 and <0.10 were interpreted
as having a trend for association.
Results
Description of the sample
The overall prevalence of anti-HCV was 1.1% (95%IC =
0.3–1.7), corresponding to 711 repeatedly reactive EIA
tests out of 66,414 blood donations in all centers in the
city of Porto Alegre between August 1995 and October
1996. A representative sample of 178 anti-HCV positive
cases and 356 controls were investigated.
Most of the donors were white (85%) and males (73%).
These characteristics were equally distributed among cases
and controls. Table 1 shows that the risk for HCV seropos-
itivity increased in 30 to 59 year-old blood donors and
schooling was inversely associated with HCV seropositiv-
ity. Donors who were illiterate or who had completed less
than five years of school were approximately three times
more likely to be anti-HCV positive when compared to
college-educated donors. First-time donors had twice the
risk for anti-HCV positivity.
Environmental exposures
Table 2 indicates that environmental exposure, such as
having lived in a shelter or boarding school, was likely to
increase the risk, but household contact with a relative
with jaundice or hepatitis was not associated with HCV se-
ropositivity. Donors who had been inmates in a prison or
who had lived in juvenile detention centers presented an
increase of approximately five times in the risk for HCV
seropositivity. However, working in closed institutions,
such as prisons, having been enrolled in the army, and oc-
cupational blood exposure did not increase the risk for a
positive anti-HCV test.
Figure 1
1st Level
2nd Level
3rd Level
Demographic
characteristics
Socioeconomic
characteristics
Environmental characteristics
Social behavior
characteristics History of 
disease
Sexual
behavior
HCV  infection
Table 1: Distribution of demographic and socioeconomic charac-
teristics of cases and controls
Variable % cases
(n = 178)
% controls
(n = 356)
OR
(95%CI)
Age (years)
18–21 6.2 15.4 1.0
22–29 21.3 26.7 2.3 (1.1–5.3)
30–39 38.2 31.5 3.5 (1.7–7.8)
40–59 34.3 26.4 3.8 (1.8–8.4)
P value 0.003
Schooling 
(years)
12–15 13.5 27.5 1.0
9–11 27.5 30.1 1.8 (1.0–3.4)
5–8 40.4 30.9 2.7 (1.6–4.8)
0–4 18.5 11.5 3.2 (1.7–6.6)
P value <0.0001
Number of 
previous 
donations
≥ 1 56.7 72.5 1.0
None 43.3 27.5 2.0 (1.3–3.0)
P value <0.0001BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/18
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Previous morbidity
Regarding history of morbidity (Table 3), the risk for HCV
seropositivity was approximately 10 times higher in blood
donors who had received blood transfusion more than 10
years before the study than in those not exposed to trans-
fusion. The effect of this factor became more evident after
adjustment for confounding factors. There was a trend for 
association of positive anti-HCV test with history of previ-
ous parenteral treatment, hospital admission for clinical
treatment, and acupuncture therapy. HCV seropositivity
was also associated with personal history of jaundice, with
an adjusted OR of 4.6.
Table 2: Environmental risk factors for HCV seropositivity among blood donors from southern Brazil
Variable % cases
 (n = 178)
% controls
 (n = 356)
Unadjusted OR
 (95%CI)
Adjusted OR
 (95%CI)*
Lived in shelter/boarding school 11.2 6.7 1.8 (0.9–3.4) 1.9 (1.0–3.6)
P value 0.08 0.07
Household contact with jaundice or hepatitis 18.5 14.0 1.3 (0.8–2.3) 1.6 (0.2–2.6)
P value 0.2 0.08
Incarceration 11.8 2.0 6.7 (2.6–17.7) 5. 2 (2.1–12.8)
P value <0.0001 0.0003
Enrolled in the army 24.7 27.5 0.8 (0.6–1.3) 0.9 (0.6–1.4)
P value 0.5 0.6
Worked at detention center or prison 2.2 2.5 0.8 (0.2–3.2) 0.8 (0.2–2.7)
P value 0.8 0.7
Occupational blood exposure 7.9 9;8 0.8 (0.4–1.6) 0.6 (0.3–1.3)
P value 0.5 0.2
*OR adjusted for age, schooling, living in a shelter/boarding school and incarceration.
Table 3: Previous morbidity as risk factor for HCV seropositivity test among blood donors in southern Brazil
Variable % cases
(n = 178)
% controls
(n = 356)
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)*
Time since last blood transfusion (years)
>10 9.6 2.5 4.2 (1.8–9.6) 9.9 (3.6–27.2)
≤ 10 19.0 24.4 0.9 (0.5–1.4) 0.8 (0.4–1.5)
P value 0.002 <0.00001
Time since hospital admission for clinical treatment (years)
≤ 10 14.0 8.7 1.9 (1.1–3.3) 2.2 (1.0–4.6)
>10 17.4 11.8 1.7 (1.0–2.9) 1.9 (1.0–3.6)
Any time 1.1 0.3 4.7 (0.4–52.3) 2.9 (0.1–57.1)
P value 0.03 0.09
Time since parenteral drug treatment (years)
≤ 10 24.2 31.2 0.8 (0.5–1.3) 0.6 (0.3–1.2)
>10 27.5 22.2 1.3 (0.8–2.0) 1.1 (0.6–2.0)
Any time 5.1 1.1 4.7 (1.4–15.9) 3.9 (1.0–15.3)
P value 0.02 0.05
Acupuncture therapy 5.6 4.2 1.4 (0.6–3.4) 2.6 (0.9–7.2)
P value 0.5 0.08
Previous jaundice 9.6 2.0 4.6 (1.8–11.9) 4.6 (1.9–11.3)**
P value <0.0001 0.001
*OR adjusted for age, schooling, living in a shelter/boarding school, incarceration, tattooing, intravenous drug use, blood transfusion, personal his-
tory of previous jaundice, number of lifetime STDs, sexual intercourse with intravenous drug user. ** OR adjusted for age, schooling, living in a shel-
ter/boarding school and incarceration.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/18
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Social and sexual behavior
Table 4 shows the association of social behavior (tattoo-
ing and intravenous drug use) and sexual characteristics
with anti-HCV seropositivity. Donors with a tattoo were
approximately four times more likely to be anti-HCV pos-
itive than donors without tattoos. The rate of intravenous
drug use was greater among cases (25.3%) in comparison
with controls (0.3%). Intravenous drug use was the
strongest independent risk factor for HCV seropositivity.
Cases were younger at their first sexual intercourse and
had a higher number of lifetime partners than controls.
However, these differences did not reach statistical signif-
icance after adjustment for confounding factors. Cases
were more likely to have had one or more sexually trans-
mitted diseases during life than controls. This resulted in
an OR six times higher for presence of anti-HCV. Sexual
intercourse with an injection drug user tripled the risk for
HCV seropositivity. Of the 178 cases, 7.9% reported hav-
ing had sexual intercourse with a partner with hepatitis
(vs. 3.4% of the controls), which was associated with a 2.7
fold (95% CI 1.0–7.4) increase in the risk for anti-HCV
positivity. This association was even more evident in indi-
viduals who had a sexual partner with hepatitis B or C.
Sexual intercourse with a partner with hepatitis B or C re-
sulted in a 3.7 fold increase in the independent risk for
HCV seropositivity.
Discussion
This case-control study shows that first-time blood do-
nors, as well as 30 to 59 year-old donors and less educated
donors were at higher risk for HCV seropositivity. In addi-
Table 4: Social and sexual behavior as risk factor for positive HCV test among blood donors from southern Brazil
Variable % cases
 (n = 178)
% controls
 (n = 356)
Unadjusted OR
 (95%CI)
Adjusted OR
 (95%CI)*
Social behavior
Tattooing 15.2 4.2 4.1 (2.0–8.3) 4.4 (1.6–11.9)
P value <0.001 0.004
Intravenous drug use 25.3 0.3 120.1 (17.7–2368.7) 105.2 (12.8–865.3)
P value <0.0001 <0.00001
Sexual behavior
Age of the first sexual intercourse (years)
≥ 18 24.9 31.1 1.0 1.0
15–17 43.5 44.7 1.2 (0.8–1.9) 0.7 (0.4–1.4)
<15 31.6 24.2 1.6 (1.0–2.7) 1.0 (0.5–1.7)
P value 0.1 0.6
Number of sexual partners (median)**
Past ten years
Male <5 / Female <2 57.1 61.5 1.0 1.0
Male ≥ 6 / Female ≥ 2 42.9 38.5 1.2 (0.8–1.7) 1.3 (0.8–2.2)
P value 0.3 0.3
Lifetime
Male ≤ 10 / Female ≤ 2 46.3 56.7 1.0 1.0
Male ≥ 11 / Female ≥ 3 53.7 43.3 1.5 (1.1–2.2) 0.8 (0.5–1.3)
P value 0.02 0.4
Number of lifetime sexually transmitted diseases
0 49.2 76.9 1.0 1.0
1 41.2 21.9 3.0 (1.9–4.5) 2.0 (1.1–3.5)
2–4 9.6 1.1 13.2 (4.0–47.7) 6.2 (1.5–25.3)
P value <0.0001 0.006
Sexual orientation
Heterosexual 84.2 95.1 1.0 1.0
Bisexual/homosexual 15.8 4.9 3.7 (1.9–7.3) 0.8 (0.3–2.2)
P value <0.0001 0.7
Sexual intercourse with intravenous drug user 8.0 2.0 4.8 (1.8–13.3) 3.5 (1.2–9.8)
P value 0.001 0.02
Sexual intercourse with a partner with hepatitis B or C virus 4.5 1.7 2.8 (0.9–9.3) 3.7 (1.1–12.8)
P value 0.04 0.04
*OR adjusted for age, schooling, living in a shelter/boarding school, incarceration, tattooing, intravenous drug use, blood transfusion, personal his-
tory of previous jaundice, number of lifetime STDs, sexual intercourse with intravenous drug user. ** 177 cases and 351 controls.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/18
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tion, our results confirm that injection drug use, blood
transfusion, incarceration, tattooing, history of sexually
transmitted diseases, and sexual intercourse with injection
drug users, partners with hepatitis, or carriers of HBV or
HCV increase the risk for a positive anti-HCV test. In the
study of risk factors associated with the presence of HCV
antibodies, the potential for bias must be ruled out. In the
present study, the sampling process enabled a representa-
tive sample of donors in the city of Porto Alegre to be de-
tected and enrolled. The inclusion of center-matched
control donors with a negative HCV test avoided bias re-
lated to differences in the recruitment policy and in the
anti-HCV test employed in each center. Immunoblot tests
and polymerase chain reaction (PCR) or transcription-
mediated amplification (TMA) were not adopted as a rou-
tine to test blood donors in Brazil. Even though the spe-
cificity of currently available EIAs for anti-HCV is high, the
positive predictive value is lower in blood donors [9]. Ac-
cordingly, we avoided to label the cases as HCV infected,
but anti-HCV seropositives.
An attempt was made to minimize recall bias by asking
cases and controls to report information about the same
period, and by using the same standardized question-
naire. Since most episodes of hepatitis C are free of symp-
toms, cases were as likely as controls to recall exposures
potentially associated with HCV infection.
When interpreting the results of this study, it is meaning-
ful to bear in mind that the eligible donors were in good
health and did not represent the general population.
First-time blood donors had twice the risk for presenting
a positive HCV test. This association is plausible, since
first-time donors have never been screened [10,11]. The
test-seeking behavior for infectious diseases is unlikely as
the Brazilian public health care system offers alternative
test sites. In addition, first-time blood donors are less like-
ly to report exposure to risk factors for HCV infection. For
instance, in the United States, the deferrable risk (defined
as estimated prevalence rate for risk behaviors that would
have been a basis for donation deferral if reported at the
time of the donor screening among first-time donors was
1.6 times greater than among repeated donors [12]. In this
study, 26% of all donors presented a history of jaundice,
incarceration, injection drug use, and tattooing. These do-
nors should have been excluded in the predonation inter-
view, according to the Brazilian criteria for blood
donation [13].
Concerning demographic variables, the increase in the
risk for HCV seropositivity between 30 and 59 years was
different to that described for donors in Australia [14] or
the United States [15,16], where the infection rate de-
clines in persons greater than 50 years old, and similar
that described in other region of our country [17]. This
pattern of transmission suggests that the risk for HCV in-
fection was greater in the distant past [18] and reached a
decreased risk of infection along generations as conse-
quence of improving sanitary and socioeconomic condi-
tions over time.
Our results show an inverse and statistically significant as-
sociation between positive HCV testing and schooling –
the risk was greater among illiterate donors or donors
with little schooling. These socioeconomic factors have
been previously described as acting through risk factors
such as illicit drug use [15] or unsafe injection practices
[19].
In terms of environmental exposure, having been incar-
cerated in a juvenile detention center or prison was the
main risk factor, independently associated with a five-fold
increase in positive HCV testing. The association between
a previous imprisonment and positive HCV testing is a
proxy of the true risks. The risk for inmates to be HCV pos-
itive has been associated with injection drug use, tattooing
and previous incarceration [20–26]. In addition, the pos-
sibility of person-to-person HCV transmission through
exposure to contaminated blood cannot be dismissed
[27].
Our study shows that exposure to blood was, and still is,
the main risk factor for HCV infection. Blood transfusion
more than 10 years ago was associated with positive HCV
testing, and the association became even stronger after ad-
justment for confounding factors. The residual risk for
transfusion-transmitted hepatitis C infection decreased af-
ter Brazilian blood centers adopted anti-HCV screening
tests 10 years ago, but it is still higher than in developed
countries [28]. As in other studies [10,11,17,29–33], we
observed that illegal injection drug use is the dominant
mode of HCV transmission, mostly due to sharing of nee-
dles or syringes [34]. Approximately 75% of Brazilian in-
jection drug users are HCV seropositive [35], and 85% of
them share needles [36]. In addition, other parenteral ex-
posure, such as tattooing, was independently associated
with HCV seropositivity. Tattooing still is not a regulated
businesses and, in the past, most of the tattoing occurred
at places where contamination were more likely. This po-
tential risk for HCV transmission in blood donors has
been previously reported [11,30]; presumably, non-sterile
or non-disposable equipment is the source of transmis-
sion [37]. HCV seropositivity was also independently as-
sociated with personal history of jaundice; however,
jaundice may be a marker of disease, rather than a risk fac-
tor. In this study, the prevalence of HCV infection was not
associated with employment in a health-related occupa-
tion. Although occupational exposure can result in infec-BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/18
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tion, [38,39] only 8.9% of blood donors were health care
workers and 32% did not handle blood samples.
The importance of sexual activity in the transmission of
HCV has not been well-established [37]. Nevertheless,
studies with blood donors suggest an association between
sexual transmission and HCV [10,11,17,31,40]. This
study detected an independent association between sexu-
al behavior and positive anti-HCV test. The results of the
logistic regression model show that the number of sexual-
ly transmitted diseases during life and sexual intercourse
with injection drug users and with HBV or HCV carriers
were independent risk factors for anti-HCV positivity.
Even though number of sexual partners and sexual orien-
tation were associated in the bivariate analysis, they were
not independent of other risk factors such as transfusion
and injection drug use by the donor or his/her sexual part-
ner. In South America, the prevalence of HCV infection in
heterosexuals attending STD clinics and with no history of
injection drug abuse (11.5%) is greater than in North
America (6.0%) and Europe (1.9%) [37]. It is speculated
that HCV transmission may be facilitated by sexually
transmitted diseases [41,42]. However, there is a possibil-
ity that HCV seropositivity associated with sexual inter-
course with injection drug users or HBV/ HCV carriers
may result from actual sexual transmission of HCV – al-
though it may also result from exposure to unreported
parenteral risk factors or from sharing certain personal
items, such as toothbrushes or razors, which can result in
accidental exposure to the partner's blood [11,33,42].
In conclusion, this case-control study confirmed some in-
dependent risk factors for anti-HCV positive test described
in other studies of blood donors. The hierarchical multi-
variate analysis identified age, schooling, incarceration,
past transfusion, tattooing, intravenous drug use, number
of sexually transmitted diseases, sexual intercourse with
injection drug users and partners with hepatitis B or C as
the main risk factors for HCV seropositivity in the present
population of southern Brazilian donors. Some character-
istics of sexual behavior were detected as independent risk
factors, suggesting that sexual intercourse is an important
source of transmission. The identification of groups at risk
and the planning of interventions aimed at controlling
HCV infection should take these findings into account.
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